Abstract
Pancreatic disease can be spatially inhomogeneous. For this reason, quantitative imaging studies of the pancreas have often targeted the 3 main anatomical pancreatic segments, head, body, and tail, traditionally using a balanced region of interest (ROI) strategy. Existing automated analysis methods have implemented whole-organ segmentation, which provides an overall quantification, but fails to address spatial heterogeneity in disease. A method to automatically refine a whole-organ segmentation of the pancreas into head, body, and tail subregions is presented for abdominal magnetic resonance imaging (MRI). The subsegmentation method is based on diffeomorphic registration to a group average template image, where the parts are manually annotated. For a new whole-pancreas segmentation, the aligned template’s part labels are automatically propagated to the segmentation of interest. The method is validated retrospectively on the UK Biobank imaging substudy (scanned using a 2-point Dixon protocol at 1.5 tesla), using a nominally healthy cohort of 100 subjects for template creation, and 50 independent subjects for validation. Pancreas head, body, and tail were annotated by multiple experts on the validation cohort, which served as the benchmark for the automated method’s performance. Good intra-rater (Dice overlap mean, Head: 0.982, Body: 0.940, Tail: 0.961, N=30) as well as inter-rater (Dice overlap mean, Head: 0.968, Body: 0.905, Tail: 0.943, N=150) agreement was observed. No significant difference (Wilcoxon rank sum test, DSC, Head: p=0.4358, Body: p=0.0992, Tail: p=0.1080) was observed between the manual annotations and the automated method’s predictions. Results on regional pancreatic fat assessment are also presented, by intersecting the 3-D parts segmentation with one 2-D multi-echo gradient-echo slice, available from the same scanning session, that was used to compute MRI proton density fat fraction (MRI-PDFF). Initial application of the method on a type 2 diabetes cohort showed the utility of the method for assessing pancreatic disease heterogeneity.
Competing Interest Statement
Authors affiliated with Perspectum Ltd are employees and stockholders
Funding Statement
This study was funded by (1) Perspectum Ltd and (2) the Engineering and Physical Sciences Research Council (EPSRC), the latter via a doctoral studentship award
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank received ethical approval from the North West Multi-centre Research Ethics Committee (MREC) and written informed consent was obtained for all subjects. This research was conducted using the UK Biobank Resource under Application Number 9914.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available to approved researchers of UK Biobank.